HLB LifeScience

Name

HLB LifeScience

Legal name

HLB Life Science Co., Ltd.

Website

https://hlb-ls.com

Company type

Public

Founded year

1998

Operating status

Operating

Headcount range

101–250 employees

Ownership category

akta.pro rank

Headquarters

HQ city

Gyeongju

HQ country

South Korea

HQ region

Asia

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical/Biotech Products: Revenue from targeted anticancer drugs including rivoceranib and pyrotinib. Rights include Korean development and sales rights, with partial revenue rights in Japan and Europe. Global rights held by Elevar Therapeutics.
2. Medical Device Manufacturing and Sales: Disposable syringes, needles, filter syringes, insulin syringes, lancets, micro-needles, IV sets, gloves, and other medical supplies. Manufacturing facilities in Anseong and Cheonan. Exports to US, Saudi Arabia, Vietnam, Mongolia.
3. Medicare Products and OEM/ODM: Reagents, consumables, and equipment for laboratories and medical facilities. Provides total solution from development to contract manufacturing (OEM/ODM). Includes in-vitro diagnostic medical devices following acquisition of AIM.
4. Human Tissue Implants: Collagen-based human tissue implant materials through PREDERM INJECT re:fill product from Olso Tech partnership. Market growing at 20.89% annually with tissue production/import cases increasing 12.4% annually.
5. Vitamin C Injection Distribution: Exclusive distribution rights for Ascor injection (high-dose vitamin C) in Korea and Japan. FDA-approved product manufactured by McGuff for hospital supply in the US. Distribution managed by HLB Therapeutics.

Go-to-market motion3 records

Distribution channels5 records

Marketing channels6 records

Core offering

HLB LifeScience develops and commercialises targeted anticancer small-molecule drugs (rivoceranib, pyrotinib, selclidemstat) and manufactures disposable medical devices including Sofjec filter syringes and veterinary hard-pack syringes. The company also supplies Medicare products (reagents, consumables, OEM/ODM IVD devices) following its acquisition of AIM, and distributes collagen-based tissue implants and FDA-approved high-dose vitamin C injection in Korea and Japan.

Product overview

HLB LifeScience is a research-focused biotech company developing targeted anticancer drugs and medical devices. The core product portfolio centers on three main targeted anticancer drugs: Rivoceranib (VEGFR-2 inhibitor for solid tumors), Pyrotinib (EGFR/HER2/HER4 inhibitor for breast and lung cancer), and Selclidemstat (LSD-1 epigenetic inhibitor for various solid tumors). The company operates two additional business divisions: a medical device division manufacturing FDA-approved disposable syringes including the Sofjec membrane filter syringe and veterinary syringes, and a Medicare division supplying reagents and consumables for medical facilities. In February 2026, HLB LifeScience expanded into human tissue transplant materials through a domestic distribution partnership with OleTech for collagen-based PREDERM INJECT re:fill products.

Differentiator

Problem solved

Functional benefit

Brands

• 소프젝 (sofjec): Membrane filter syringe — a disposable syringe with FDA 510(k) clearance for the US market.
• 프리덤 인젝트 리필 (PREDERM INJECT re:fill)
• 아스코르주 (Ascor injection)

Products and services

• Rivoceranib (리보세라닙) Oral targeted anticancer drug that selectively inhibits VEGFR-2 to suppress tumor angiogenesis; reverses multi-drug resistance via P-glycoprotein inhibition and synergises with immune checkpoint inhibitors through PD-L1 upregulation. Used for solid tumors including gastric, liver, and salivary gland cancer.
• Pyrotinib (파이로티닙) Oral targeted anticancer drug inhibiting EGFR, HER2, and HER4 for HER2-positive metastatic breast cancer and HER2 exon20 insertion non-small cell lung cancer.
• Selclidemstat (세클리뎀스타트) First-in-class epigenetic anticancer drug that reversibly inhibits LSD-1 (lysine-specific demethylase 1) to normalise gene expression and suppress cancer cells in solid tumors including lung, breast, prostate, and Ewing sarcoma.
• Disposable Syringes and Medical Devices (including Sofjec filter syringe) Disposable syringes, needles, filter syringes (Sofjec with FDA 510(k)), insulin syringes, lancets, micro-needles, IV sets, and surgical gloves manufactured at Anseong and Cheonan plants and exported to US, Saudi Arabia, Vietnam, and Mongolia.
• Veterinary Hard-Pack Syringe Veterinary syringe in hard plastic case for large-animal treatment, on-site veterinary care, and vaccinations, featuring enhanced portability, hygiene, and breakage resistance.
• Medicare Products (reagents, consumables, OEM/ODM) Reagents, consumables, and equipment for research laboratories and medical facilities, plus total-solution OEM/ODM contract manufacturing for specimen collection, blood collection, and other IVD medical devices.
• PREDERM INJECT re:fill (프리덤 인젝트 리필) Acellular homologous dermis injectable using Olso Tech's Allo-PELT process with collagen content up to 80.42% and average particle size under 100 micrometres; supplied in 0.3cc, 0.5cc, 1.0cc, and 3.0cc volumes for ligament, tendon, muscle and joint reconstruction and regeneration.
• Ascor (아스코르주) High-Dose Vitamin C Injection FDA-approved high-dose vitamin C injection used as an anticancer adjuvant to reduce oxidative stress and improve patient quality of life during treatment, supplied through hospital channels.
• Cell Therapy Products (Bio Artificial Space, LiverCell / LifeLiver) Cell therapy products including Bio Artificial Space cell and tissue engineering products and LifeLiver (LiverCell) cell therapy for acute liver failure patients awaiting transplantation.

Quantifiable outcome

• Overall survival (mOS) 22.1 months vs 15.2 months (sorafenib) in liver cancer Phase 3
• +9 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Ten partnerships are on record, tiered core and minor.

• Olso TechcoreChannel Partner/ Reseller/ Distributor · 4 February 2026Domestic distribution partnership for PREDERM INJECT re:fill collagen-based human tissue implant material. HLB LifeScience secured exclusive domestic distribution rights. Plans to establish tissue bank by Q1 and expand nationally through orthopedics and neurosurgery departments.
• Olso TechcoreStrategic or Co-development Partner · 4 February 2026Uses Olso Tech's proprietary Allo-PELT process with up to 80.42% collagen content for tissue reconstruction and regeneration products.
• Allison MedicalcoreChannel Partner/ Reseller/ Distributor · 1 January 2024Partnership with US medical device company Allison Medical for export of veterinary hard-pack syringes. First shipment of 8 tons initiated with 180 tons planned by year-end. Allison Medical is ranked #1 in US veterinary medical device distribution. Expected to generate approximately 150 billion KRW in exports by year 3.
• Lead Discovery Center (LDC)coreStrategic or Co-development Partner · 9 August 2023Partnership with Germany's LDC (spin-off from Max Planck Society) for next-generation targeted anticancer substance. Acquired global rights to novel compound targeting specific gene transcription processes in damaged cancer cells. Includes upfront payment, milestone payments, and sales royalties.
• HLB Group Companies (HLB, HLB LifeScience, HLB Pharma)coreStrategic or Co-development Partner · 17 August 2022MOU among HLB group companies for rivoceranib commercialization. Elevar holds global rights (excluding Korea, China), HLB LifeScience holds Korean rights and partial European/Japanese rights, HLB Pharma provides manufacturing.
• NeoKenBio (네오켄바이오)minorStrategic or Co-development Partner · 12 April 2022MOU for joint R&D on medical marijuana-based pharmaceuticals. Researching anticancer and epilepsy treatment applications from cannabinoid compounds.
• Hengrui Medicine (항서제약)coreOEM/ Whitelabel/ Licensing Partner · 1 January 2020Licensed pyrotinib (EGFR/HER2/HER4 inhibitor) for exclusive Korean development and sales in 2020. HLB LifeScience conducting Phase 3 for breast cancer and non-small cell lung cancer.
• Elevar TherapeuticscoreStrategic or Co-development PartnerUS subsidiary managing global rivoceranib development (excluding Korea and China). Led global Phase 3 CARES 310 trial across 13 countries with 543 patients. Submitted FDA NDA for liver cancer combination therapy with camrelizumab.
• Hengrui Medicine (항서제약)coreStrategic or Co-development PartnerChinese pharmaceutical company holding China rights for rivoceranib and developing pyrotinib. Rivoceranib approved in China for gastric cancer (3rd line) and liver cancer (2nd line). Pyrotinib licensed to HLB LifeScience for Korea in 2020.
• HLB TherapeuticscoreChannel Partner/ Reseller/ DistributorDistribution partner for Ascor high-dose vitamin C injection (FDA-approved). Utilizes HLB Therapeutics' largest-scale ultra-low temperature facilities and distribution network in Korea for hospital supply.

Scale indicators15 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• SK Biopharmaceuticals: Korean biopharma with FDA-approved central nervous system drugs and global commercial ambitions (cenobamate). Comparable as a Korean-listed innovative pharma pursuing US FDA approval for proprietary drug assets, with similar pipeline-to-market transition challenges.
• Hanmi Pharmaceutical: Korean innovator biopharma focused on novel drug development across oncology, diabetes, and autoimmune diseases. Comparable as a KOSDAQ-listed Korean pharma with pipeline-driven strategy, multiple licensing partnerships, and similar enterprise scale.
• Jiangsu Hengrui Medicine: Original developer and licensor of rivoceranib (apatinib) and pyrotinib. As HLB LifeScience's licensing partner and source of its two core oncology assets, Hengrui is the most directly comparable peer—both companies are innovating around the same compounds with overlapping clinical data and commercial strategies.
• Yuhan Corporation: Korean biopharmaceutical company with diversified prescription drug, OTC, and consumer health businesses. Closely comparable to HLB LifeScience as a Korean publicly-listed pharma with similar revenue scale, multi-product portfolio, and strategic focus on both innovative drugs and legacy healthcare products.

Broad incumbents

• Nipro: Japanese medical device and pharmaceutical company with a substantial disposable syringe and medical supplies business. Comparable as another major Asian syringe manufacturer competing in the export markets (US, Middle East, Southeast Asia) where HLB LifeScience is establishing distribution.
• Daiichi Sankyo: Japanese pharmaceutical company with strong oncology franchise including ADC platform. Comparable as an Asia-headquartered innovative pharma with substantial oncology pipeline, global regulatory ambitions, and similar deal structures around in-licensed assets.
• Terumo: Japanese global medical device manufacturer with extensive syringe, needle, and IV product portfolio. Comparable as a large established Asian medical device manufacturer competing in the same syringe and injection device category that HLB LifeScience's medical device division targets.
• BeiGene: Chinese oncology biotech with global commercial operations, FDA-approved drugs (zanubrutinib), and pipeline across hematology and solid tumors. Comparable as a globally commercializing oncology biotech from Asia pursuing similar regulatory and commercial milestones.
• Becton Dickinson (BD): Global leader in syringes, injection systems, and medical devices with FDA-cleared product portfolio across hundreds of SKUs. Comparable as the dominant incumbent in the syringe category that HLB LifeScience is targeting for US market entry with Sofjec and veterinary hard-pack syringes.

Others

• Elevar Therapeutics: US subsidiary that holds global rights to rivoceranib (excluding Korea/China) and is the strategic co-development partner that led the CARES 310 Phase 3 trial. Highly relevant as the entity controlling the global commercial path for HLB's lead asset.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@HyundaiLifeboat_hlb

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries4 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HLB LifeScience